期刊文献+

CTC检测在预测肺癌复发转移及患者预后中的意义 被引量:11

Implication of CTC detecting in the predicting recurrence and metastasis of lung cancer and prognosis of patients
下载PDF
导出
摘要 探讨肺癌患者循环肿瘤细胞(CTC)检测在复发转移及预后预测中的应用效果。选择71例肺癌患者设为观察组,所有患者经过化疗、手术治疗,术后3年随访。选择同期在本院体检健康者55例为对照组。采用免疫磁珠富集联合免疫荧光染色法测定两组CTC阳性表达情况,分析CTC阳性率与肺癌患者复发、转移及预后的相关性。结果显示,观察组CTC阳性率显著高于对照组;肺癌患者复发、转移与CTC阳性率呈显著正相关性;肺癌患者预后与CTC阳性率呈显著负相关性。结果提示,CTC在肺癌患者中阳性率较高,能预测患者复发、转移,有助于评估患者预后。 To investigate the detecting of circulating tumor cells(CTC)in prediction of recurrence,metastasis and prognosis in the patients with lung cancer.Seventy-one patients with lung cancer were enrolled in the observation group.All patients underwent chemotherapy and surgery,and 3 years follow-up period.55 cases with healthy physical examination at the same time served as the control group.The positive expression of CTC was detected by immunomagnetic beads enrichment combined with immunofluorescence staining.The correlation between the recurrence,metastasis and prognosis of patients with lung cancer and CTC positive rate were analyzed.The results showed,positive rate of CTC in the observation group was significantly higher than that in the control group.The positive rate of CTC and the recurrence and metastasis were positively correlated.The prognosis of lung cancer patients was negatively correlated with the positive rate of CTC.The study indicated that CTC has a high positive rate in lung cancer patients,which can predict recurrence,metastasis and assess the prognosis of patients.
作者 李娜 姚丽 LI Na;YAO Li(Clinical Laboratory,East Clinic of the Second People's Hospital of Lianyungang,Lianyungang 222000,Jiangsu,China)
出处 《中南医学科学杂志》 CAS 2020年第5期490-493,共4页 Medical Science Journal of Central South China
关键词 循环肿瘤细胞 肺癌 复发 转移 预后 circulatory tumor cells lung cancer recurrence metastasis prognosis
  • 相关文献

参考文献12

二级参考文献53

  • 1曾沥琼,杨竹.循环肿瘤细胞在卵巢癌预后中的研究进展[J].医学信息(医学与计算机应用),2014,0(14):604-605. 被引量:2
  • 2李珺,王泳,张雪松,路明.肺癌患者纤维蛋白原及D-二聚体与肿瘤分期、转移的关系[J].中华临床医师杂志(电子版),2011,5(21):6457-6459. 被引量:23
  • 3中华人民共和国国家卫生和讨划生育委员会.2011年城市居民年龄别疾病别死亡率.《2012中国卫生统计年鉴》,2013.
  • 4Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin, 2011, 61(2): 91-112.
  • 5Mok TS, Wu YL, Kongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N EnglJ Med, 2009, 361(10): 947-957.
  • 6Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cen lung cancer with mutated EGFR. N EnglJ Med, 2010, 362(25): 2380-2388.
  • 7Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
  • 8Sequist LV, YangJC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR nautations.J Clin Oncol, 2013, 31(27): 3327-3334.
  • 9Yang H, Cai L, Zhang Y, et al. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn, 2014, 16(5): 558-563.
  • 10Yang H, Yang X, Zhang Y, et al. Erlotinib in combination with pemetrexed/ cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure. Target Oncol, 2015, 10(1): 135-140.

共引文献152

同被引文献146

引证文献11

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部